SECTION I: ESTIMATION OF COSTS
|
1 |
Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result. |
| … in terms of IPR protection | |
| License file application 700 euros, maintenance 350 euros/year | |
| …in terms of product development | |
| Testing equipment: 60.000
Testing engineer: 60.000 Bioref test lab: 120.000 |
|
| …in terms of mass production | |
| There are no mass production costs | |
| … in terms of marketing | |
| Marketing will start after the first year of development. In the second year will be allocated 20.000 euro and the next years the marketing cost will follow a steady plan 10.000 per year. | |
|
2 |
Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs |
||||||
|
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
|||
| Fixed costs |
40,000 |
50,000 |
60,000 |
70,000 |
80,000 |
||
| Personnel |
60,000 |
30,000 |
35,000 |
40,000 |
50,000 |
||
| Other running costs |
180,000 |
12,000 |
14,000 |
16,000 |
18,000 |
||
| Marketing costs |
0 |
20,000 |
10,000 |
10,000 |
10,000 |
||
| TOTAL EXPECTED COSTS |
280,000 |
112,000 |
119,000 |
136,000 |
158,000 |
||
| Price per Unit |
35000 |
35000 |
35000 |
35000 |
35000 |
||
| Number of Units |
0 |
3 |
9 |
12 |
16 |
||
| TOTAL Expected Revenues |
0 |
105,000 |
315,000 |
420,000 |
560,000 |
||
| CASH FLOW REQUIRED (REVENUES-COSTS) |
-280,000 |
-7,000 |
196,000 |
284,000 |
402,000 |
||
| TOTAL CAPITAL required for five years | 287.000 to cover the first two years of operations and 50.000 euro for running costs. Total 337.000 | ||||||
SECTION 2: QUALITATIVE FACTORS
|
3 |
Dimension of identified target groups |
| The identified target group for industrial Bioref designs assumes a price 35000 euro per industrial design. The firs year is allocated for development of the Bioref lab. The market is wide (farmers, agricultural associations) but the target goal is moderate considering the fact that Bioref is a new Technology. | |
|
4 |
Evaluation of financial Risks for R&D result |
| The financial risk are described in terms of emerging competitive technologies that are possible to emerge in the first year of development. Since there is a competitive research environment time to market is an important success factor. | |
SECTION 3: IDENTIFICATION OF FINANCING SOURCES
After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)
| 1. European Funding
Define relevance of the product with the following potential funding sources and comment |
| FP7 Energy
Intelligent energy
|
| 2. National Funding |
| Low availability of research programmes at national level. |
| 3. Private funding |
| Venture capitals, joint ventures with private funding from large web service providers |
| 4. Other |
SECTION 3: FINAL EVALUATION
| It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)… |
| The recommended funding scheme is joint venture with the manufacturers tat could take up bioref prototype in to industrial production. The joint venture assumes common share and agreement on IPR and agreement on industrial design capitalization. |
Decision of evaluation (Please keep only the appropriate)
The R&D has a high potential.
Nikos Zaharis
